Gut Bacteria Linked to High Blood Pressure and Depression
|
By LabMedica International staff writers Posted on 17 Sep 2019 |

Image: This infographic illustrates the connection between the brain, central nervous system and other organs and how they interact with a person\'s gut microbes to show different patterns from people with high blood pressure plus depression; high blood pressure without depression; depression with healthy blood pressure; or healthy subjects without depression or high blood pressure (Photo courtesy of Professor Bruce R. Stevens, PhD).
The microbiome is the genetic material of all the microbes, bacteria, fungi, protozoa and viruses that live on and inside the human body. The number of genes in all the microbes in one person's microbiome is 200 times the number of genes in the human genome.
A study of human gut bacteria, known as the gut microbiome, suggests that high blood pressure with depression may be a completely different disease than high blood pressure without depression. The gut may be targeted someday to prevent, diagnose and selectively treat different forms of high blood pressure with or without depression.
Scientists from the University of Florida College of Medicine (Gainesville, FL, USA) made a study of bacteria in the gut identified differences between people with high blood pressure compared to those with high blood pressure plus depression. They isolated DNA (deoxyribonucleic acid, the carrier of genetic information) from gut bacteria obtained from the stool samples of 105 volunteers. They used a new technique involving artificial-intelligence software to analyze the bacteria, which revealed four distinct types of bacterial genes and signature molecules.
Surprisingly, the investigators discovered unique patterns of bacteria from people with 1) high blood pressure plus depression; 2) high blood pressure without depression; 3) depression with healthy blood pressure; or 4) healthy subjects without depression or high blood pressure. The authors concluded that the results suggest different medical mechanisms of high blood pressure that correlate with signature molecules produced by gut bacteria. These molecules are thought to impact the cardiovascular system, metabolism, hormones and the nervous system.
Bruce R. Stevens, PhD, a Professor of Physiology & Functional Genomics, Medicine and Psychiatry and the lead author of the study, said, “People are 'meta-organisms' made up of roughly equal numbers of human cells and bacteria. Gut bacteria ecology interacts with our bodily physiology and brains, which may steer some people towards developing high blood pressure and depression. We believe we have uncovered new forms of high blood pressure: 'Depressive Hypertension' (high blood pressure with depression), which may be a completely different disease than 'Non-Depressive Hypertension' (high blood pressure without depression), which are each different from 'Non-Hypertensive Depression.” The study was presented at the American Heart Association's Hypertension 2019 Scientific Sessions on September 5, 2019, in New Orleans, LA, USA.
Related Links:
University of Florida College of Medicine
A study of human gut bacteria, known as the gut microbiome, suggests that high blood pressure with depression may be a completely different disease than high blood pressure without depression. The gut may be targeted someday to prevent, diagnose and selectively treat different forms of high blood pressure with or without depression.
Scientists from the University of Florida College of Medicine (Gainesville, FL, USA) made a study of bacteria in the gut identified differences between people with high blood pressure compared to those with high blood pressure plus depression. They isolated DNA (deoxyribonucleic acid, the carrier of genetic information) from gut bacteria obtained from the stool samples of 105 volunteers. They used a new technique involving artificial-intelligence software to analyze the bacteria, which revealed four distinct types of bacterial genes and signature molecules.
Surprisingly, the investigators discovered unique patterns of bacteria from people with 1) high blood pressure plus depression; 2) high blood pressure without depression; 3) depression with healthy blood pressure; or 4) healthy subjects without depression or high blood pressure. The authors concluded that the results suggest different medical mechanisms of high blood pressure that correlate with signature molecules produced by gut bacteria. These molecules are thought to impact the cardiovascular system, metabolism, hormones and the nervous system.
Bruce R. Stevens, PhD, a Professor of Physiology & Functional Genomics, Medicine and Psychiatry and the lead author of the study, said, “People are 'meta-organisms' made up of roughly equal numbers of human cells and bacteria. Gut bacteria ecology interacts with our bodily physiology and brains, which may steer some people towards developing high blood pressure and depression. We believe we have uncovered new forms of high blood pressure: 'Depressive Hypertension' (high blood pressure with depression), which may be a completely different disease than 'Non-Depressive Hypertension' (high blood pressure without depression), which are each different from 'Non-Hypertensive Depression.” The study was presented at the American Heart Association's Hypertension 2019 Scientific Sessions on September 5, 2019, in New Orleans, LA, USA.
Related Links:
University of Florida College of Medicine
Latest Pathology News
- Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
- AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
- IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
- AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
- 3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
- Blood-Based Method Tracks Gene Activity in the Living Brain
- FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
- AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
- Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
- AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
- FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
- New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
- AI System Analyzes Routine Pathology Slides to Predict Cancer Outcomes
- New Tissue Mapping Approach Identifies High-Risk Form of Diabetic Kidney Disease
- Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment
Channels
Clinical Chemistry
view channel
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more
Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
Previous studies have linked vitamin C–rich diets with lower risk of cognitive impairment in older adults. However, few investigations have directly examined blood plasma vitamin C in relation to brain... Read more
Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
Cancer’s altered metabolism complicates how clinicians detect and monitor tumors, because nutrient use can shift with context and time. Measuring small-molecule metabolites that distinguish malignant from... Read more
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read moreMolecular Diagnostics
view channel
Ultrasensitive HPV Blood Test Predicts Early Recurrence in Head and Neck Cancer
Human papillomavirus (HPV)-associated head and neck cancers are frequently treated with surgery, but some patients experience recurrence due to residual microscopic disease. Postoperative decisions about... Read more
New Library Normalization and Amplification Tools Support Oncology Sequencing
High-throughput next-generation sequencing (NGS) laboratories continue to grapple with uneven library pooling and amplification artifacts that can degrade variant calling accuracy and increase reruns.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
Accurate classification of brain and spinal cord tumors increasingly depends on molecular profiling alongside histology, but access to such testing remains limited and results can take about two weeks.... Read more
IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Deficient DNA mismatch repair is an established predictive biomarker for response to immune checkpoint inhibitors, yet access to standardized assessment has varied across tumor types. Cancer remains the... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Open-Source Consortium Aims to Standardize Digital Pathology Workflows
Digital pathology is expanding rapidly as laboratories adopt whole-slide imaging and computational tools to meet growing diagnostic and biomarker-testing demand. However, fragmented software infrastructure... Read more




.jpg)



